Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
- Associated Therapies
- -
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT01421173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 40
- Registration Number
- NCT01306019
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT01237951
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT01200329
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Characterize the Effect of Heparin on Palifermin Activity
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 44
- Registration Number
- NCT01163097
- Locations
- 🇺🇸
New Orleans Center for Clinical Research (NOCCR), Knoxville, Tennessee, United States
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Conditions
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 3
- Registration Number
- NCT00881556
- Locations
- 🇺🇸
The Children's Hospital, Aurora, Colorado, United States
🇺🇸Morgan Stanley Children's Hospital of NYP, New York, New York, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00728585
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT00701688
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 5
- Registration Number
- NCT00626639
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Sherif S. Farag
- Target Recruit Count
- 9
- Registration Number
- NCT00593554
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.